Hostname: page-component-6bf8c574d5-w79xw Total loading time: 0 Render date: 2025-02-28T06:12:38.479Z Has data issue: false hasContentIssue false
  • English
  • Français

Dramatic resolution of a prenatally diagnosed massive cardiac rhabdomyoma in left ventricle with everolimus therapy in a neonate

Published online by Cambridge University Press:  03 February 2025

Roma Verma ,
Akshay Desale  and
Balu Vaidyanathan Open the ORCID record for Balu Vaidyanathan [Opens in a new window]
Roma Verma
Affiliation:
The Fetal Cardiology Division, Department of Pediatric Cardiology and Department of Radiology, Amrita University, AIMS Ponekkara PO, Amrita Institute of Medical Sciences, Kochi, Kerala, India
Akshay Desale
Affiliation:
The Fetal Cardiology Division, Department of Pediatric Cardiology and Department of Radiology, Amrita University, AIMS Ponekkara PO, Amrita Institute of Medical Sciences, Kochi, Kerala, India
Balu Vaidyanathan*
Affiliation:
The Fetal Cardiology Division, Department of Pediatric Cardiology and Department of Radiology, Amrita University, AIMS Ponekkara PO, Amrita Institute of Medical Sciences, Kochi, Kerala, India
*
Corresponding author: Balu Vaidyanathan; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Brief Report
Information
Cardiology in the Young , First View , pp. 1 - 3
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kwiatkowska, J, Wałdoch, A, Meyer-Szary, J, Potaż, P, Grzybiak, M. Cardiac tumors in children: a 20-year review of clinical presentation, diagnostics and treatment. Adv Clin Exp Med 2017; 26: 319–326. DOI: 10.17219/acem/62121.CrossRefGoogle ScholarPubMed
Franz, DN, Capal, JK. MTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Orphanet J Rare Dis 2017; 12: 51. DOI: 10.1186/s13023-017-0596-2.CrossRefGoogle ScholarPubMed
Isaacs, H Jr. Fetal and neonatal cardiac tumors. PediatrCardiol 2004; 25: 252–273. DOI: 10.1007/s00246-003-0590-4.Google ScholarPubMed
Dahdah, N. Everolimus for the treatment of tuberous sclerosis complex-related cardiac rhabdomyomas in pediatric patients. J Pediatr 2017; 190: 21–26.e7. DOI: 10.1016/j.jpeds.2017.06.076.CrossRefGoogle ScholarPubMed
Demir, HA, Ekici, F, Yazal Erdem, A, Emir, S, Tunç, B. Everolimus:a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. Pediatrics 2012; 130: e243–e247. DOI: 10.1542/peds.2011-3476.CrossRefGoogle Scholar
Stelmaszewski, EV, Parente, DB, Farina, A et al. Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. In The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial. Cardiology in the Young, 2020: pp. 1–9. DOI: 10.1017/S104795111900314.Google Scholar
Nespoli, LF, Albani, E, Corti, C, et al. Efficacy of everolimus low-dose treatment for cardiac rhabdomyomas in neonatal tuberous sclerosis: Case Report and Literature Review. Pediatr Rep 2021; 13: 104–112. DOI: 10.3390/pediatric13010015.CrossRefGoogle ScholarPubMed
Babaoğlu, K, Başar, EZ, Usta, E, Yılmaz, EH, Günlemez, A. Effect of different dose regimens of everolimus in a series of neonates with giant cardiac rhabdomyomas. Cardiol Young 2023; 33: 2291–2296. DOI: 10.1017/S1047951123000094.CrossRefGoogle Scholar
Sagiv, E, Chikkabyrappa, SM, Conwell, J, Lewin, M, Chun, TUH. Use of everolimus to treat cardiac rhabdomyomas and incessant arrhythmias in a newborn: benefits and complications. Ann Pediatr Cardiol 2022; 15: 58–60. DOI: 10.4103/apc.apc_11_21.CrossRefGoogle Scholar
Bornaun, H, Öztarhan, K, Erener-Ercan, T, et al. Regression of cardiac rhabdomyomas in a neonate after everolimus treatment. Case Rep Pediatr 2016; 2016: 8712962. DOI: 10.1155/2016/8712962.Google Scholar
Breathnach, C, Pears, J, Franklin, O, Webb, D, McMahon, CJ. Rapid regression of left ventricular outflow tract rhabdomyoma after sirolimus therapy. Pediatrics 2014; 134: e1199–e1202. DOI: 10.1542/peds.2013-3293.CrossRefGoogle ScholarPubMed
Ng, LY, McGuinness, J, Prendiville, T, et al. Cardiac rhabdomyomas presenting with critical cardiac obstruction in neonates and infants: treatment strategies and outcome, a single-center experience. Pediatr Cardiol 2024; 45: 1132–1141. DOI: 10.1007/s00246-024-03420-0.CrossRefGoogle ScholarPubMed
Cleary, A, McMahon, CJ. Literature review of international mammalian target of rapamycin inhibitor use in the non-surgical management of haemodynamically significant cardiac rhabdomyomas. Cardiol Young 2020; 30: 923–933. DOI: 10.1017/S104795112000147X.CrossRefGoogle ScholarPubMed
Northrup, H, Aronow, ME, Bebin, EM, et al. International Tuberous Sclerosis Complex Consensus Group. In Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021; vol. 123: pp. 50–66. DOI: 10.1016/j.pediatrneurol.2021.07.011.Google Scholar
Supplementary material: File

Verma et al. supplementary material

Verma et al. supplementary material
Download Verma et al. supplementary material(File)
File 13.6 MB